[go: up one dir, main page]

BRPI0600275A - prótese coronária liberadora de composição medicamentosa para prevenção e tratamento da reestenose e processo de fabricação - Google Patents

prótese coronária liberadora de composição medicamentosa para prevenção e tratamento da reestenose e processo de fabricação

Info

Publication number
BRPI0600275A
BRPI0600275A BRPI0600275-7A BRPI0600275A BRPI0600275A BR PI0600275 A BRPI0600275 A BR PI0600275A BR PI0600275 A BRPI0600275 A BR PI0600275A BR PI0600275 A BRPI0600275 A BR PI0600275A
Authority
BR
Brazil
Prior art keywords
restenosis
prevention
treatment
manufacturing process
drug composition
Prior art date
Application number
BRPI0600275-7A
Other languages
English (en)
Inventor
Alexandre Do Canto Zago
Alcides Jose Zago
Original Assignee
Brz Biotecnologia Ltda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brz Biotecnologia Ltda filed Critical Brz Biotecnologia Ltda
Priority to BRPI0600275-7A priority Critical patent/BRPI0600275A/pt
Priority to AU2007203734A priority patent/AU2007203734A1/en
Priority to JP2008547811A priority patent/JP2009521961A/ja
Priority to EP07700097.4A priority patent/EP1986714A4/en
Priority to PCT/BR2007/000004 priority patent/WO2007076588A1/en
Priority to CNA2007800017509A priority patent/CN101370533A/zh
Priority to CA002636299A priority patent/CA2636299A1/en
Publication of BRPI0600275A publication Critical patent/BRPI0600275A/pt
Priority to US12/215,936 priority patent/US20090012605A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08—Materials for coatings
    • A61L31/10—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Surgery (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

PRóTESE CORONáRIA LIBERADORA DE COMPOSIçãO MEDICAMENTOSA PARA PREVENçãO E TRATAMENTO DA REESTENOSE E PROCESSO DE FABRICAçãO. é descrita uma prótese coronária liberadora de composição medicamentosa para a prevenção e tratamento da reestenose e processo de fabricação que compreende entre 10,0 a 500,0 Ug/cm¬ 2¬ da superfície da prótese coronária revestida com rapamicina (sirolimus) ou análogos e entre 0,01 a 20,0 Ug/mm¬ 2¬ da superfície da prótese coronária revestida com paclitaxel ou análogos.
BRPI0600275-7A 2006-01-03 2006-01-03 prótese coronária liberadora de composição medicamentosa para prevenção e tratamento da reestenose e processo de fabricação BRPI0600275A (pt)

Priority Applications (8)

Application Number Priority Date Filing Date Title
BRPI0600275-7A BRPI0600275A (pt) 2006-01-03 2006-01-03 prótese coronária liberadora de composição medicamentosa para prevenção e tratamento da reestenose e processo de fabricação
AU2007203734A AU2007203734A1 (en) 2006-01-03 2007-01-03 Coronary stent that releases medicamentuous composition to prevent and treat restenosis and fabrication process
JP2008547811A JP2009521961A (ja) 2006-01-03 2007-01-03 再狭窄予防治療のために薬物組成を放出する冠状動脈ステントとその組み立て工程
EP07700097.4A EP1986714A4 (en) 2006-01-03 2007-01-03 CORONARY STENT THAT RELEASES A DRUG COMPOSITION FOR PREVENTING AND TREATING RESTENOSIS AND METHOD OF MANUFACTURING
PCT/BR2007/000004 WO2007076588A1 (en) 2006-01-03 2007-01-03 Coronary stent that releases medicamentuous composition to prevent and treat restenosis and fabrication process
CNA2007800017509A CN101370533A (zh) 2006-01-03 2007-01-03 释放药物组合物以防止和治疗再狭窄的冠状动脉支架和制造方法
CA002636299A CA2636299A1 (en) 2006-01-03 2007-01-03 Coronary artery stent releasing a drug composition for prevention and treatment of restenosis
US12/215,936 US20090012605A1 (en) 2006-01-03 2008-07-01 Coronary stent that releases medicamentuous composition to prevent and treat restenosis and fabrication process

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BRPI0600275-7A BRPI0600275A (pt) 2006-01-03 2006-01-03 prótese coronária liberadora de composição medicamentosa para prevenção e tratamento da reestenose e processo de fabricação

Publications (1)

Publication Number Publication Date
BRPI0600275A true BRPI0600275A (pt) 2007-10-02

Family

ID=38227860

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0600275-7A BRPI0600275A (pt) 2006-01-03 2006-01-03 prótese coronária liberadora de composição medicamentosa para prevenção e tratamento da reestenose e processo de fabricação

Country Status (8)

Country Link
US (1) US20090012605A1 (pt)
EP (1) EP1986714A4 (pt)
JP (1) JP2009521961A (pt)
CN (1) CN101370533A (pt)
AU (1) AU2007203734A1 (pt)
BR (1) BRPI0600275A (pt)
CA (1) CA2636299A1 (pt)
WO (1) WO2007076588A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8057816B2 (en) 1997-09-26 2011-11-15 Abbott Laboratories Compositions and methods of administering paclitaxel with other drugs using medical devices
US8257726B2 (en) 1997-09-26 2012-09-04 Abbott Laboratories Compositions, systems, kits, and methods of administering rapamycin analogs with paclitaxel using medical devices
US7637940B2 (en) * 2007-07-06 2009-12-29 Boston Scientific Scimed, Inc. Stent with bioabsorbable membrane
WO2011086574A2 (en) * 2010-01-18 2011-07-21 Concept Medical Research Private Limited Formulations of nano-carriers and methods of preparing the same

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050163818A1 (en) * 1996-11-05 2005-07-28 Hsing-Wen Sung Drug-eluting device chemically treated with genipin
US6273913B1 (en) * 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
US20030129215A1 (en) * 1998-09-24 2003-07-10 T-Ram, Inc. Medical devices containing rapamycin analogs
US8029561B1 (en) * 2000-05-12 2011-10-04 Cordis Corporation Drug combination useful for prevention of restenosis
US7807211B2 (en) * 1999-09-03 2010-10-05 Advanced Cardiovascular Systems, Inc. Thermal treatment of an implantable medical device
EP2314293B1 (en) * 2001-01-16 2017-01-04 Vascular Therapies, LLC Implantable device containing resorbable matrix material and rapamycin for preventing or treating vasuloproliferative diseases
US7771468B2 (en) * 2001-03-16 2010-08-10 Angiotech Biocoatings Corp. Medicated stent having multi-layer polymer coating
US20030065382A1 (en) * 2001-10-02 2003-04-03 Fischell Robert E. Means and method for the treatment of coronary artery obstructions
AU2003228858A1 (en) * 2002-05-02 2003-11-17 Scimed Life Systems, Inc. Energetically-controlled delivery of biologically active material from an implanted medical device
US20050163821A1 (en) * 2002-08-02 2005-07-28 Hsing-Wen Sung Drug-eluting Biodegradable Stent and Delivery Means
EP1572029B1 (en) * 2002-11-07 2010-03-24 Abbott Laboratories Method of loading beneficial agent to a prosthesis by fluid-jet application
US20050064005A1 (en) * 2003-08-13 2005-03-24 Dinh Thomas Q. Active agent delivery systems including a miscible polymer blend, medical devices, and methods
ITTO20040056A1 (it) * 2004-02-05 2004-05-05 Sorin Biomedica Cardio Spa Stent per l'erogazione endoliminale di principi o agenti attivi
KR100891148B1 (ko) * 2004-02-28 2009-04-06 헤모텍 아게 의료용 표면의 생체적합성 코팅, 방법 및 그 용도
JP4949227B2 (ja) * 2004-03-19 2012-06-06 アボット・ラボラトリーズ バルーンおよびプロテーゼからの多剤送達
US20050288481A1 (en) * 2004-04-30 2005-12-29 Desnoyer Jessica R Design of poly(ester amides) for the control of agent-release from polymeric compositions

Also Published As

Publication number Publication date
CA2636299A1 (en) 2007-07-12
EP1986714A1 (en) 2008-11-05
AU2007203734A1 (en) 2007-07-12
WO2007076588A1 (en) 2007-07-12
EP1986714A4 (en) 2014-01-22
US20090012605A1 (en) 2009-01-08
JP2009521961A (ja) 2009-06-11
CN101370533A (zh) 2009-02-18
WO2007076588B1 (en) 2007-08-23

Similar Documents

Publication Publication Date Title
PA8759601A1 (es) Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
EP2099448A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF RESTENOSIS
ECSP10010042A (es) Compuestos y composiciones como moduladores de la actividad de gpr119
BRPI0908194B8 (pt) Uso de uma anexina a5 recombinante, e stent de eluição de fármaco
TN2009000211A1 (en) Antiviral composition and method of use
MX2009005308A (es) Composiciones que comprenden peroxido de benzoilo, al menos un derivado del acido naftoico y al menos un compuesto del tipo polimeros de poliuretano o derivados de estos y sus usos.
WO2008092006A3 (en) Antimicrobial compositions
CR9989A (es) Composición farmacéutica que comprende al menos un medicamento contra el cáncer y al menos un polímero
WO2008087488A3 (en) Expandable medical device for the treatment and prevention of cardiovascular diseases
ATE451130T1 (de) Phospholipid und verunreinigungsbeständige beschichtungszusammensetzungen
CL2008003699A1 (es) Nanopartícula que comprende pioglitazona y un polímero biocompatible, preparación farmacéutica que la contiene; stent (endoprótesis vascular) que la porta; y su uso en la profilaxis o tratamiento de enfermedades arterioescleróticas.
WO2009005269A3 (en) Pharmaceutical composition for preventintion and treatment of restenosis comprising isoxazole derivatives
DOP2006000235A (es) Derivados de acidos dicarboxilicos y su uso
ECSP088763A (es) Nuevas combinaciones terapéuticas para el tratamiento de la depresión
AR060019A1 (es) Composicion farmaceutica, producto y metodo de tratamiento para un trastorno cognitivo y usos de un inhibidor de acetilcolinesterasa y un antagonista de 5- ht6 en la fabricacion de un medicamento para el tratamiento de un trastorno cognitivo
PL2083809T3 (pl) Kompozycja dietetyczna lub farmaceutyczna zawierająca tricykliczne diterpeny do leczenia depresji
ATE453416T1 (de) Medizinischer stent mit einer kombination aus melatonin und paclitaxel
WO2008021124A3 (en) Compositions and drug-delivery systems comprising rapamycin analogs and paclitaxel
MX2010007242A (es) Composiciones farmaceuticas que comprenden granulos de lipasa microbiana purificada y metodos para prevenir o tratar trastornos digestivos.
WO2007120897A3 (en) Compositions and intraluminal devices for inhibiting vascular stenosis
DE602007011975D1 (de) Thiadiazolderivate zur behandlung neurodegenerativer krankheiten
BRPI0600285A (pt) compostos farmacêuticos contendo nanopartìculas úteis para tratamento de lesões reestenóticas
BRPI0600275A (pt) prótese coronária liberadora de composição medicamentosa para prevenção e tratamento da reestenose e processo de fabricação
ATE458748T1 (de) Proteinbindende methotrexat-derivate und diese enthaltende arzneimittel
WO2006113718A3 (en) Compositions for the treatment of neoplasms

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 13A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2495 DE 30-10-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.